CD274 and neoplasm: MSI-Hi CRCs were shown to upregulate expression of several immune checkpoints (PD-1, PD-L1, CTLA-4, LAG-3, IDO) in the TILs, stroma, or tumor invasive front compartments, enabling the tumor cells to survive.